Cargando…

Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)

INTRODUCTION: Argatroban is licensed for patients with heparin-induced thrombocytopenia and is conventionally monitored by activated partial thromboplastin time (APTT) ratio. The target range is 1.5 to 3.0 times the patients’ baseline APTT and not exceeding 100 s, however this baseline is not always...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guy, Susan, Kitchen, Steve, Makris, Michael, M. Maclean, Rhona, Saccullo, Giorgia, Vanveen, Joost J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Manuscript
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689594/ https://www.ncbi.nlm.nih.gov/pubmed/34905962 http://dx.doi.org/10.1177/10760296211066945

Ejemplares similares

Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)
por: Makris, Michael, et al.
Publicado: (2021)

Vaccine-induced thrombosis and thrombocytopenia (VITT); Exploring the unknown
por: Sunder, Ashok, et al.
Publicado: (2022)

Vaccination-induced thrombocytopenia and thrombosis (VITT) and pre-VITT: Do not miss (or misdiagnose) the new member of the thrombotic thrombocytopenias family
por: Noyé, Mickaël, et al.
Publicado: (2022)

Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis
por: Yuan, Yao, et al.
Publicado: (2023)

Most cases of Thrombosis and Thrombocytopenia Syndrome (TTS) post ChAdOx-1 nCov-19 are Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)
por: Makris, Michael, et al.
Publicado: (2021)

Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT
por: Myllylahti, Lasse, et al.
Publicado: (2022)

Argatroban in the management of heparin-induced thrombocytopenia
por: Babuin, Luciano, et al.
Publicado: (2010)

Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices
por: Swan, D., et al.
Publicado: (2021)

Renal Vein Thrombosis and Pulmonary Embolism Secondary to Vaccine-induced Thrombotic Thrombocytopenia (VITT)
por: Cliff-Patel, Nikita, et al.
Publicado: (2021)

Audit of pathology requesting behaviour in the setting of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Maclean, Marsali, et al.
Publicado: (2022)

Vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Warkentin, Theodore E.
Publicado: (2022)

Understanding vaccine‐induced thrombotic thrombocytopenia (VITT)
por: Dix, Caroline, et al.
Publicado: (2022)

Late-Onset Vaccine-Induced Immune Thombotic Thrombocytopenia (VITT) with Cerebral Venous Sinus Thrombosis
por: Saleh, Maruan, et al.
Publicado: (2022)

Vaccine‐induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources
por: Greinacher, Andreas, et al.
Publicado: (2022)

Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis
por: Colarossi, Giorgia, et al.
Publicado: (2021)

Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time
por: Spencer, Akpan, et al.
Publicado: (2011)

Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Greinacher, Andreas, et al.
Publicado: (2022)

Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Gabarin, Nadia, et al.
Publicado: (2022)

AZD-1222: Vaccine-induced thrombosis with thrombocytopenia (VITT) and arterial and venous thrombotic stroke : case report
Publicado: (2022)

Second-dose VITT: rare but real
por: Pavord, Sue, et al.
Publicado: (2022)

Arterial intracranial thrombosis as the first manifestation of vaccine-induced immune thrombotic thrombocytopenia (VITT): a case report
por: Mancuso, Michelangelo, et al.
Publicado: (2022)

Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)—Insights from Clinical Cases, In Vitro Studies and Murine Models
por: Dabbiru, Venkata A. S., et al.
Publicado: (2023)

Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II
por: Grouzi, Elisavet
Publicado: (2014)

Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial
por: Tardy-Poncet, Brigitte, et al.
Publicado: (2015)

Argatroban/heparin: Heparin-induced thrombocytopenia and lack of efficacy: case report
Publicado: (2020)

Argatroban/heparin: Heparin-induced thrombocytopenia and lack of efficacy: case report
Publicado: (2021)

A Patient with Severe Fever with Thrombocytopenia Syndrome, Activated Partial Thromboplastin Time Prolongation, and Transient Antiphospholipid Antibodies
por: Tsukamoto, Yutaka, et al.
Publicado: (2022)

COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis
por: Hafeez, Muhammad Usman, et al.
Publicado: (2021)

Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)
por: Aston, Daniel, et al.
Publicado: (2022)

Argatroban /AZD-1222/fondaparinux-sodium: Vaccine-induced immune thrombosis with thrombocytopenia and recurrent and fatal intracranial haemorrhage: case report
Publicado: (2021)

Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies
por: Kanack, Adam J., et al.
Publicado: (2022)

Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis
por: Marchandot, Benjamin, et al.
Publicado: (2021)

Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency
por: Di Micco, Pierpaolo, et al.
Publicado: (2021)

COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) and Cerebral Venous Sinus Thrombosis (CVST)- Lessons for India
por: Khan, Erum, et al.
Publicado: (2022)

Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019
por: Ogawa, Yoshihiko, et al.
Publicado: (2020)

A Case Report and Literature Review on Argatroban Refractory Heparin-Induced Thrombocytopenia
por: Deen, Imad U., et al.
Publicado: (2022)

Vaccine-induced thrombotic thrombocytopenia (VITT): first report from India
por: John, Christy V., et al.
Publicado: (2022)

Role of Anticoagulation and IVIG in Treatment of Vaccine-Induced Thrombotic Thrombocytopenia (VITT)
por: Tariq, Anosha, et al.
Publicado: (2022)

The Effect of Sugammadex on Prothrombin and Activated Partial Thromboplastin Time
por: Samara, Evangelia, et al.
Publicado: (2021)

Vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous sinus thrombosis (CVST): a case report from Malaysia
por: Liam, Christopher Chin Keong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gsjtt04mjmaputsfvd7se5bs7a